Based on the above findings, we concluded that anlotinib inhibits the migration and invasion of human ESCC cell lines KYSE-30 and TE-1 by inhibiting the expression of MMP-9, and the addition of raltitrexed enhances the inhibitory effect of anlotinib on cell migration and invasion. This evidence concerns the gene MMP9 and esophageal squamous cell carcinoma.